Vericel Corporation

Valuation Analysis

About the Company

Vericel Corporation en bref

Vericel Corporation (VCEL) is currently trading at 34,96 € with a market capitalization of 1,8 Md €. The trailing P/E ratio stands at 93.26x, with a forward P/E of 47.07x. The 52-week range spans from 25,24 € to 37,98 €; the current price is 8% below the yearly high. Year-over-year revenue growth stands at +30.1%. The net profit margin stands at 7.35%.

💰 Dividende

Vericel Corporation currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

7 analystes évaluent Vericel Corporation (VCEL) au consensus : Achat Fort. L'objectif de cours moyen est de 48,32 €, soit un potentiel de +38.23% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 36,61 € à 61,02 €.

Vericel Corporation : la thèse d'investissement en détail

Vericel Corporation (VCEL) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Top-line momentum is unusually strong with revenue expanding 30.1% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 74.84%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 38.23% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Short interest sits at 12.81% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

The EV/EBITDA multiple of 68.6x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The forward P/E of 47.07x is meaningfully below the trailing 93.26x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 38.23% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to market-like volatility, elevated short interest (12.81%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Vericel Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.